Hadlima Alternatives in Iowa
Compare generic and therapeutic alternatives to Hadlima (adalimumab-bwwd (biosimilar)) available at Iowa pharmacies. Save up to 82% on your prescription — no insurance required.
Top Alternatives in Iowa
Hyrimoz (adalimumab biosimilar)
generic
High-concentration citrate-free Humira biosimilar
Avg cash price: $1100/mo
Humira (brand adalimumab)
brand
Original brand — same molecule at 5× the cost
Avg cash price: $6800/mo
Methotrexate
therapeutic
DMARD alternative — much cheaper, often combined with biologics
Avg cash price: $30/mo
Iowa Prescription Assistance Programs
Iowa Medicaid Rx
Prescription drug benefits for Iowa Medicaid (Iowa Health and Wellness Plan) enrollees.
Eligibility: Low-income Iowa adults up to 138% FPL, plus children and pregnant women at higher income thresholds.
Frequently Asked Questions
What is Hadlima and is it the same as Humira?
Hadlima (adalimumab-bwwd) is an FDA-approved biosimilar to Humira. It contains the same active molecule and is rated interchangeable in many states — meaning a pharmacist can substitute it for Humira without calling the doctor.
How much cheaper is Hadlima compared to Humira?
Hadlima typically costs 70–80% less than brand Humira. Brand Humira can exceed $6,000/month list price; biosimilars like Hadlima and Hyrimoz are often $1,000–$1,500/month.
Is Hadlima safe and effective?
FDA biosimilar approval requires demonstration of no clinically meaningful difference in safety or efficacy compared to the reference product (Humira). Millions of patients worldwide now use adalimumab biosimilars.
What is the difference between Hadlima and Hyrimoz?
Both are adalimumab biosimilars. Hadlima comes in standard and high-concentration (100 mg/mL) formulations. Hyrimoz is citrate-free (fewer injection site stinging). Both are FDA-interchangeable with Humira.
Can Script Unlock help access Hadlima?
Some Script Unlock pharmacies carry adalimumab biosimilars. Post your prescription — specialty pharmacies in the network may offer competitive pricing on Hadlima and other biosimilars.